Faculty profile
Maxime Chénard-Poirier
Back to facultyResearch
Read how they describe their research on their Université Laval profile.
Latest funding
- $153,000
Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study
CIHR · 2019 · Co-investigator
No publications available.
Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study
Principal investigators: Gangloff, Anne
Keywords: Acceptability Of The Regimen; Biomarkers (Lipid Profile, Tumoral Ldlr, Npc1l1, Srb1); Cholesterol-Lowering Drugs (Pcsk9 Inh, Statins, Ezetimibe); Clinical Trial (Non-Randomized, Open-Label); Dose-Limiting Toxicities; Estimates Of Progression-Free Survival; Estimates To Perform Power Calculation; Feasibility And Proof-Of-Concept Study; Folfirinox; Metastatic Pancreatic Ductal Adenocarcinoma
From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.